# Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.

> **NCT00406562** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 30 (—)

## Conditions studied

- Tetanus
- Diphtheria
- Acellular Pertussis

## Interventions

- **BIOLOGICAL:** Boostrix

## Key facts

- **NCT ID:** NCT00406562
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** 30 (—)
- **Last updated:** 2016-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00406562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00406562, "Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00406562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*